Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kaitlyn R Rouillard"'
Autor:
Kaitlyn R Rouillard, Christopher P Esther, William J Kissner, Lucas M Plott, Dean W Bowman, Matthew R Markovetz, David B Hill
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0294120 (2024)
People with muco-obstructive pulmonary diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) often have acute or chronic respiratory infections that are difficult to treat due in part to the accumulation of hyperconce
Externí odkaz:
https://doaj.org/article/72bb598001344edaa99e0f9f178812c0
Publikováno v:
mSphere, Vol 7, Iss 4 (2022)
ABSTRACT The pathological properties of airway mucus in cystic fibrosis (CF) are dictated by mucus concentration and composition, with mucins and DNA being responsible for mucus viscoelastic properties. As CF pulmonary disease progresses, the concent
Externí odkaz:
https://doaj.org/article/c90a0a37058d42b885c7d2990e83176b
Autor:
Steffen B. Wiegand, Lisa Traeger, Huan K. Nguyen, Kaitlyn R. Rouillard, Anna Fischbach, Francesco Zadek, Fumito Ichinose, Mark H. Schoenfisch, Ryan W. Carroll, Donald B. Bloch, Warren M. Zapol
Publikováno v:
Redox Biology, Vol 39, Iss , Pp 101826- (2021)
Rationale: Inhalation of nitric oxide (NO) exerts selective pulmonary vasodilation. Nitric oxide also has an antimicrobial effect on a broad spectrum of pathogenic viruses, bacteria and fungi. Objectives: The aim of this study was to investigate the
Externí odkaz:
https://doaj.org/article/1ed8d9ccad5644c0a131a74d3e20da81
Autor:
Kaitlyn R. Rouillard, Matthew R. Markovetz, William J. Kissner, William L. Boone, Lucas M. Plott, David B. Hill
Publikováno v:
Biofilm. 5:100104
Autor:
Efrat Ozeri-Galai, Lital Friedman, null Ofra-Barchad-Avitzur, Matthew R Markovetz, William Boone, Kaitlyn R Rouillard, Chava D Stampfer, Yifat S Oren, David B Hill, Batsheva Kerem, Gili Hart
The last years have shown enormous advancement in the therapeutic potential of RNA-related treatments, specifically for antisense oligonucleotide (ASO)-based drugs, leading to increased numbers of ASO regulatory approvals. In this study we focus on S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0633060cb2f46556fe1d306a533247ba
https://doi.org/10.1101/2023.01.09.23284328
https://doi.org/10.1101/2023.01.09.23284328
Publikováno v:
J Cyst Fibros
Background The combination of antibacterial and mucolytic actions makes nitric oxide (NO) an attractive dual-action cystic fibrosis (CF) therapeutic. The delivery of any therapeutic agent through pathological mucus is difficult, and the use of inhale
Autor:
Mona Jasmine R. Ahonen, Mark H Schoenfisc, Dakota J. Suchyta, Micah D. Brown, Kaitlyn R. Rouillard, Jackson R. Hall
Publikováno v:
ACS Biomater Sci Eng
Nitric oxide (NO) is a broad-spectrum antibacterial agent, making it an attractive alternative to traditional antibiotics for treating infections. To date, a direct comparison of the antibacterial activity of gaseous NO (gNO) versus water-soluble NO-
Autor:
P. Sears, Stephen M. Stick, W. Kissner, David B. Hill, Matthew R. Markovetz, L. Ostrowski, Kaitlyn R. Rouillard, R. Howard
Publikováno v:
Journal of Cystic Fibrosis. 20:S168-S169
Autor:
Kaitlyn R. Rouillard, Alex M Pistiolis, Mark H. Schoenfisch, R. McDonald, Olivia P Novak, Lei Yang, Mona Jasmine R. Ahonen
Publikováno v:
ACS infectious diseases. 7(1)
Antibiotic resistance in bacteria is a major global threat and a leading cause for healthcare-related morbidity and mortality. Resistant biofilm infections are particularly difficult to treat owing to the protective biofilm matrix, which decreases bo
Autor:
W. Kissner, Mark H. Schoenfisch, Sara E. Maloney, Kaitlyn R. Rouillard, Matthew R. Markovetz, David B. Hill
Publikováno v:
Journal of Cystic Fibrosis. 20:S239